ATS 2025: GSK strengthens argument for twice-annual depemokimab

May 22, 2025 - 06:00

ATS 2025: GSK strengthens argument for twice-annual depemokimab

Read the original article

Tags:

Previous Article

WHO secures 20% funding increase amid US shortfall

BioNTech to invest up to $1.34bn in UK R&D

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Sanofi to make €1bn biomanufacturing investment in France

Sanofi to make €1bn biomanufacturing investment in France

May 15, 2024

Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023

Revenue growth for 13 of top 20 biopharmas with obesity...

Aug 1, 2024

Green chemistry: Navigating growing ESG challenges in pharma manufacturing

Green chemistry: Navigating growing ESG challenges in p...

May 16, 2025